Glyburide increases risk in patients with diabetes mellitus after emergent percutaneous intervention for myocardial infarction - A nationwide study

International Journal of Cardiology

Volumn 152, Issue 3, 2011, Pages 327-331

  Jorgensen C H ^a   Gislason, G H ^a   Bretler, D ^a   Sorensen R ^a   Norgaard, M L ^a   Hansen, M L ^a   Schramm, T K ^a   Abildstrom, S Z ^b,c   Torp Pedersen, C ^a   Hansen, P R ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Cardiovascular epidemiology; Cardiovascular outcomes; Metformin; Myocardial infarction; Percutaneous coronary intervention; Sulfonylureas

Indexed keywords

ACARBOSE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOOP DIURETIC AGENT; METFORMIN; ORAL ANTIDIABETIC AGENT; SPIRONOLACTONE; TOLBUTAMIDE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; DENMARK; DIABETES MELLITUS; FEMALE; GLYBURIDE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; REGISTRIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 80055028057     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.07.027     Document Type: Article

References (26)

1. E.M. Antman, M. Hand, and P.W. Armstrong 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 Writing Committee Circulation 117 2008 296 329
2. J.A. Beckman, M.A. Creager, and P. Libby Diabetes and atherosclerosis: epidemiology, pathophysiology, and management JAMA 287 2002 2570 2581
3. B. O'Rourke Evidence for mitochondrial K+ channels and their role in cardioprotection Circ Res 94 2004 420 432
4. F. Gribble, S. Tucker, S. Seino, and F. Ashcroft Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels Diabetes 47 1998 1412 1418
5. D.J. Hausenloy, and D.M. Yellon Protecting the myocardium at time of reperfusion-meeting report of the Hatter Institute 4th International Workshop on Cardio-protection Basic Res Cardiol 100 2005 383 386
6. M. Madsen, M. Davidsen, S. Rasmussen, S.Z. Abildstrom, and M. Osler The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry J Clin Epidemiol 56 2003 124 130
7. J.V. Tu, P.C. Austin, R. Walld, L. Roos, J. Agras, and K.M. McDonald Development and validation of the ontario acute myocardial infarction mortality prediction rules J Am Coll Cardiol 37 2001 992 997
8. C.L. Meinert, G.L. Knatterud, T.E. Prout, and C.R. Klimt A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results Diabetes 19 1970 789 830 [Suppl]
9. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 352 1998 837 853
10. J.M. Evans, S.A. Ogston, A. Emslie-Smith, and A.D. Morris Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin Diabetologia 49 2006 930 936
11. A.D. Rao, N. Kuhadiya, K. Reynolds, and V.A. Fonseca Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies Diab Care 31 2008 1672 1678
12. J.A. Johnson, S.R. Majumdar, S.H. Simpson, and E.L. Toth Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes Diab Care 25 2002 2244 2248
13. D.M. Yellon, and J.M. Downey Preconditioning the myocardium: from cellular physiology to clinical cardiology Physiol Rev 83 2003 1113 1151
14. J.P. Riveline, N. Danchin, F. Ledru, M. Varroud-Vial, and G. Charpentier Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications Diabetes Metab 29 2003 207 222
15. J.J. Meier, B. Gallwitz, W.E. Schmidt, A. Mugge, and M.A. Nauck Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 90 2004 9 12
16. H. Klepzig, G. Kober, and C. Matter Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide Eur Heart J 20 1999 439 446
17. M.M. Mocanu, H.L. Maddock, G.F. Baxter, C.L. Lawrence, N.B. Standen, and D.M. Yellon Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide Circulation 103 2001 3111 3116
18. Kao J, Tobis J, McClelland RL, et al. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol 2004;93:1347-1350, A1345.
19. G.S. Bhamra, D.J. Hausenloy, and S.M. Davidson Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening Basic Res Cardiol 103 2008 274 284
20. K.N. Garratt, P.A. Brady, N.L. Hassinger, D.E. Grill, A. Terzic, and D.R. Holmes Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction J Am Coll Cardiol 33 1999 119 124
21. H.R. Andersen, T.T. Nielsen, and K. Rasmussen A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction N Engl J Med 349 2003 733 742
22. T.-M. Lee, and T.-F. Chou Impairment of myocardial protection in type 2 diabetic patients J Clin Endocrinol Metab 88 2003 531 537
23. S.P. Johnsen, T.B. Monster, and M.L. Olsen Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs Am J Ther 13 2006 134 140
24. N. Danchin, G. Charpentier, and F. Ledru Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry Diabetes Metab Res Rev 21 2005 143 149
25. P. Ferdinandy, R. Schulz, and G.F. Baxter Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning Pharmacol Rev 59 2007 418 458
26. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150